开发和验证用于预测临床阶段的高风险病理的诺姆图,以预测1A左上叶肺腺癌的临床阶段
Defeng Luo1,2, Kunsong Su2, Yu Han2
1China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
BMC surgery
|October 3, 2025
概括
这项研究开发了一种名图,用于预测早期左上叶肺腺癌的高风险病理. 该工具帮助外科医生量身定制治疗,以获得更好的患者结果.
科学领域:
- 在瘤学瘤学.
- 胸部外科手术 胸部外科手术
- 诊断成像 诊断成像 诊断成像
背景情况:
- 在早期的肺腺癌中,准确的手术前识别高风险病理对于手术决策至关重要.
- 左上叶 (LUL) 肺腺癌具有独特的外科考虑.
- 这项研究侧重于临床阶段IA LUL腺癌.
研究的目的:
- 开发和验证用于预测临床阶段IA LUL肺腺癌的高风险病理学的名录.
- 帮助外科医生量身定制手术方法,并识别潜在的辅助治疗患者.
主要方法:
- 545名临床阶段IA LUL腺癌患者的回顾性审查.
- 随机划分为培训 (80%) 和验证 (20%) 集.
- 多变量后勤回归,LASSO回归,ROC曲线,校准图,DCA,以及用于名ogram构建和评估的引导重新采样.
主要成果:
- 在19.1%的患者中发现了高风险病理 (固体/微毛囊型,复杂的腺体,STAS,LVI).
- 确定了四个独立的预测因素:CEA升高,CT瘤大小增加,冷部位的侵入性组织学,CT平均值更高.
- 诺莫格拉姆显示出优异的区别 (AUC 0.837培训,0.865验证) 与稳定的内部验证.
结论:
- 诺米图集结了临床,放射和手术内数据,以进行个性化手术前风险评估.
- 这种工具可以帮助手术方法量身定制和识别患者进行延长切除或辅助治疗.
- 未来的外部验证是必要的,以确认可通用性.
更多相关视频
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
643
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
489
相关概念视频
Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...
